Key result
The introduction of NOACs in Slovenia expanded the capacity of anticoagulation clinics, increasing the treated population by more than 50% over 5 years while medication expenditures increased approximately 10-fold.
Why the study?
How does the introduction of NOACs affect anticoagulation care management and expenditures in Slovenia?
Observational (n=54,576)
How does the introduction of NOACs affect anticoagulation care management and expenditures in Slovenia?
The introduction of NOACs in Slovenia significantly expanded the treated population and increased medication costs without disrupting the core organization of anticoagulation clinics.
Answers are grounded in this paper and cite their sources.
NOAC introduction expanded anticoagulation access in Slovenia amid 10-fold cost increases; leaves open cost-effectiveness and generalizability to other systems.
Anticoagulation treatment was recently improved by the introduction of novel oral anticoagulants (NOACs). Using a combination of qualitative and quantitative methods, this study explores the effects of the introduction of NOACs on anticoagulation care in Slovenia. Face-to-face interviews with key stakeholders revealed evolvement and challenges of anticoagulation care from different perspectives. Obtained information was further explored through the analysis of nationwide data of drug prescriptions and realization of health care services. Simplified management of anticoagulation treatment with NOACs and their high penetration expanded the capacity of anticoagulation clinics, and consequentially the treated population increased by more than 50 % in the last 5 years. The main challenge concerned the expenditures for medicines, which increased approximately 10 times in just a few years. At the same time, the anticoagulation clinics and their core organisation were not affected, which is not expected to change, since they are vital in delivering high-quality care.
No takes yet. Share an insight, caveat, or question.
Janžič et al. (2017) conducted an observational in Anticoagulation treatment (n=54,576). Novel oral anticoagulants (NOACs) vs. Vitamin K antagonists (VKAs) was evaluated on Treated population size and medication expenditures. The introduction of NOACs in Slovenia expanded the capacity of anticoagulation clinics, increasing the treated population by more than 50% over 5 years while medication expenditures increased approximately 10-fold.
Synapse has enriched 10 related papers. Consider them for comparative context: